苏州大学药学院欢迎您!

叶娜

发布者:金雪明发布时间:2018-12-04浏览次数:3942

叶娜.JPG


 

姓名:叶娜

职务职称:博士,特聘副教授,硕士生导师

联系电话:0512-65881161

联系邮箱:yena@suda.edu.cn

联系地址:苏州市工业园区仁爱路199号药学院云轩楼1225

 

个人简介:

 

一、    学习与工作经历

2016.9–至今:苏州大学,药学院,特聘副教授

2013.6–2016.8:美国德州大学医学分部,博士后

2008.09-2013.06中国科学院上海药物研究所,药物化学,理学博士

2004.09-2008.07沈阳药科大学,国家基础药学理科基地班,理学学士

 

二、    研究方向

1)靶向神经精神性重大疾病的药物研发

2)抗肿瘤药物的设计与合成

3) 有机方法学在药物研发中的应用

 

三、    主要学术科研成果 

长期从事药物化学及化学生物学研究,通过运用有机合成方法,结合现代药物设计新理念和新方法,进行中枢神经系统疾病和肿瘤新药研究。至今在J Med Chem, Chem Rev, Cancer lett, Eur J Med Chem,ACS Infect Dis, ACS Chem Neurosci, Acta Pharmacol SinOrg. Biomol. Chem.等药物化学与有机化学期刊上发表SCI论文40余篇,其中第一及通讯作者近20篇,高被引论文1篇。共申报国内外发明专利10余项其中4项中国专利已授权,1项专利已转让。并编写“十二五”国家重点图书《新药研发案例研究:明星药物如何从实验室走向市场》第十章。另外,曾设计开发的靶向聚腺苷二磷酸核糖聚合酶PARP抑制剂SOMCL-9112已申报化学药品1.1类抗肿瘤新药,即希明哌瑞及其片剂,获得了卫生部优先评审品种推荐及中国药监局颁发的新药临床实验批件,目前正在临床试验中。至今主持在研或已完成国家自然科学基金项目和江苏省自然科学基金项目以及苏州市民生科技项目各1项。同时担任Curr Top Med Chem杂志的客座编辑,完成以Drug Discovery by Targeting Mutant KRAS为主题的专刊出版工作。

 

代表性论文如下:

1)        Ye, N.;* Qin, W.; Tian, S.; Xu, Q.; Wold, E. A.; Zhou, J.; Zhen, X. C. Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases. J. Med. Chem. 2020, 63, 15187-15217.

2)        Mao Q, Zhang B, Li W, Tian S, Shui W, Ye, N.* Identification of Novel 1-O-Substituted Aporphine Analogues as Potent 5-HT2C Receptor Agonists.  ACS Chem. Neurosci.,2020, 11, 549−559.

3)        Mao, Q.; Qin, W.; Zhang, A.; Ye, N.* Overview of recent advances on dopaminergic strategies for Parkinson’s disease. Acta Pharmacol. Sin.,2020, 41, 471-482.

4)        Xu, Q.; Li B.; Ma, Y.; Sun, F.; Gao, Y.; Ye, N.* K2S2O8-HFIP Synergistic Promoted para-selective sp3 C-H Bond Diarylation of Glycine Esters. Org. Biomol. Chem., 2020, 18, 666-670.

5)        Ye, N.*; Drug Discovery by Targeting Mutant KRAS. Curr. Top. Med. Chem. 2019, 19, 2079-2080. (Editoral; Guest editor)

6)        Ye, N.*; Xu, Q.; Li, W.; Wang, P.; Zhou, J., Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors. Curr. Top. Med. Chem. 2019, 19, 2114-2127.

7)        Li, .B.; Mao, Q.; Zhou, J.; Liu, F.; Ye, N.* HFIP-Promoted Michael Reactions: Direct para-Selective C-H Activation of Anilines with Maleimides. Org. Biomol. Chem., 2019, 17, 2242-2246.

8)        Ye, N.*; Li, B.; Mao, Q.; Wold, E. A.; Tian, S.; Allen, J. A.; Zhou, J. Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target. ACS Chem. Neurosci.,2019, 10, 190−200.

9)        Yuan, B.; Ye, N.;# Song, S. S.; Wang, Y. T.; Song, Z.; Chen, H. D.; Chen, C. H.; Huan, X. J.; Wang, Y. Q.; Su, Y.; Shen, Y. Y.; Sun, Y. M.; Yang, X. Y.; Chen, Y.; Guo, S. Y.; Gan, Y.; Gao, Z. W.; Chen, X. Y.; Ding, J.; He, J. X.; Zhang, A.;Miao, Z. H.Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Cancer lett., 2017,386, 47-56.(#并列第一作者)

10)    Ye, N.; Zhu, Y.; Liu, Z.; Mei, F. C.; Chen, H.; Wang, P.; Cheng, X.; Zhou, J. Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydra- zonoyl cyanide analoguesas potent EPAC antagonists. Eur. J. Med. Chem. 2017,134, 62-71.

11)    Ye, N.; Shi, P.-Y.; Zhou, J. Therapetic Potential of Spirooxindoles as Antiviral Agents. ACS Infect. Dis., 2016,2, 382-292. (高被引论文)

12)    Ye, N.; Zhu, Y.; Chen, H.; Liu, Z.; Mei, F. C.; Wild, C.; Chen, H.; Cheng, X.; Zhou, J. Structure–Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N’-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists. J. Med. Chem., 2015, 58, 6033-6047.

13)    Ye, N.; Ding, Y.; Wild, C.; Shen, Q.; Zhou, J. Small molecule inhibitors targeting activator protein 1 (AP-1). J. Med. Chem.,2014,57, 6930-6948.

14)    Ye, N.; Song, Z.; Zhang, A. Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT1A Receptors as New Antipsychotical or Anti-Parkinsonian Agents. Curr. Med. Chem.,2014,21, 437-457.

15)    Ye, N.; Neumeyer, J. L.; Baldessarini, R. J.; Zhen, X.; Zhang, A. Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders. Chem. Rev.,2013,113, PR123-178.

16)    Ye, N.; Chen, C. H.; Chen, T.; Song, Z.; He, J. X.; Huan, X. J.; Song, S. S.; Liu, Q.; Chen, Y.; Ding, J.; Xu, Y.; Miao, Z. H.; Zhang, A. Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors. J. Med. Chem.,2013,56, 2885-2903.

17)    Zhang, H.; Ye, N.; # Zhou, S.; Guo, L.; Zheng, L.; Liu, Z.; Gao, B.; Zhen, X.; Zhang, A. Identification of N-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson’s Agent Possessing a Dopamine D2 and Serotonin 5-HT1A Dual-Agonist Profile. J. Med. Chem.,2011, 54, 4324–4338. (#并列第一作者)